$GKOS

Thurman Alex R. sold $1.6M of GKOS

Thurman Alex R. (SVP & CHIEF FINANCIAL OFFICER) sold 10,000 shares of GLAUKOS Corp (GKOS) at $155.00 ($1.55M total) on 2026-07-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thurman Alex R.
Published Jul 14, 2026, 12:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 14, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GKOS
Neutral
high confidence
Mentioned
$GKOS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The newest concrete fact is the CFO’s open-market sale of 10,000 shares at $155/share, totaling $1.55M, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale for sentiment, but there is no new fundamental catalyst in the filing.

03

What to watch

Insider sales can be scheduled regardless of company outlook; without accompanying buys or new company disclosures, the trading signal is weak.

Relevance 5/10Novelty 3/10Timing: New SEC Form 4 filed 2026-07-13, covering a sale dated 2026-07-09.

Background

The article is an SEC Form 4 insider transaction disclosure for Glaukos Corp, identifying the CFO and the sale details.

Company-level read

Ticker impact

$GKOSNeutralHigh confidence
Context

Glaukos CFO Thurman Alex sold 10,000 shares on 2026-07-09 at $155/share under a pre-arranged 10b5-1 plan, per Form 4.

Expected impact

Likely minimal near-term price impact; any reaction is more sentiment-driven than fundamental.

Evidence & confidence

The filing is an insider transaction (not a guidance, contract, or regulatory event). The presence of a pre-arranged 10b5-1 plan typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through; this is company-specific insider activity without operational or regulatory details.

None indicated.

None indicated.

Counterpoint

The sale could be purely liquidity-driven and not a bearish signal, especially given the stated 10b5-1 plan.

Key entities

  • GLAUKOS Corp

    Company whose CFO filed the insider sale on Form 4.

  • Thurman Alex R.

    SVP and Chief Financial Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GKOSHighAI 8/10

Glaukos Market Cap More Than Doubles in a Year to $11B

Glaukos Corp.'s market cap has more than doubled to $11 billion in a year, driven by expanding into new eye care markets and record Q2 sales of $185.6 million. The company raised its full-year guidance and saw its shares rise over 15% post-earnings. Key products include iDose TR for glaucoma and Epioxa for keratoconus, with several other products in development.

$GKOSMed

GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

Glaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.

$GKOSMedAI 8/10

Glaukos Corp stock hits all-time high at 190.27 USD

Glaukos Corp (GKOS) hit an all-time high of $190.27, with a 111.6% increase over the past year. Its market cap is $11.03 billion, and revenue grew 41.55% over the last twelve months. Q2 2026 revenue was $185.6 million, up 49.5% year-over-year, exceeding estimates. Analysts raised price targets, with Truist Securities setting it at $215.

$GKOSMedAI 8/10

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.